ADCT today
$1.41-$0.00 (-0.35%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourExpanding
1 hourLeaning Bullish
15 minBullish
5 minStrong Bullish
Daily trend turns up above $4.98
Key levels
Resistance$3.10
Resistance$1.70
Support$1.39
Support$1.06
Latest news & SEC filings
SEC FilingADC Therapeutics SA filed a shelf registration for future offerings (Form S-3)
EarningsADC Therapeutics Posts Q3 2026 Financials
SEC FilingADC Therapeutics SA filed a report on a major company event (Form 8-K)
All ADCT news →About ADC Therapeutics
ADC Therapeutics is a biotechnology company that creates antibody-drug conjugates, which are targeted therapies designed to fight cancers such as lymphomas. Its main approved medicine, ZYNLONTA, is sold in the United States and Europe, and the company has other candidates in clinical testing. It works with outside manufacturers and partners to produce and commercialize its products.
Based on the company's 10-K filed Mar 10, 2026.
NYSE · Healthcare
ADC Therapeutics SA (ADCT)
What Is the Price Target for ADCT?
SEPT Low Target
$2.00
SEPT Mid Target
$5.00
SEPT High Target
$8.00
Analyst Consensus
$5.00
Is ADCT a Buy or Sell Right Now?
Thesis
- •Revenue growing 14.8% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ADCT.
Start Free Trial →Is ADCT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$5.00
34
Moat Score
NONE
5/9
Piotroski Score
-7.0
Altman Z-Score
What Is Smart Money Doing with ADCT?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Azelby Robert | director | Sale | 12,600 | $39K | Jun 3, 2026 |
| Squarer Ron | director | Sale | 15,196 | $47K | Jun 3, 2026 |
| Sandor Victor | director | Sale | 12,600 | $39K | Jun 3, 2026 |
| Monges Viviane | director | Sale | 2,596 | $8K | Jun 3, 2026 |
| Hug Peter | director | Sale | 2,156 | $7K | Jun 3, 2026 |
| BIZZARI JEAN-PIERRE | director | Sale | 12,600 | $39K | Jun 3, 2026 |
| Coughlin Timothy | director | Sale | 12,600 | $39K | Jun 3, 2026 |
| Azelby Robert | director | Buy | 45,000 | - | Jun 1, 2026 |
| Squarer Ron | director | Buy | 45,000 | - | Jun 1, 2026 |
| Sandor Victor | director | Buy | 45,000 | - | Jun 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ADCT Growth Story
Revenue YoY
14.8%
3yr Revenue CAGR
-27.1%
EPS Growth YoY
30.86%
FCF Growth YoY
-13.4%
Revenue Trend
ACCELERATING
Dark Pool Trades for ADCT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ADCT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:03:15 | $1.40 | 1,200 | $$2K | MIDPOINT |
| 20:02:26 | $1.40 | 2,908 | $$4K | BUY |
| 19:47:53 | $1.40 | 4,100 | $$6K | MIDPOINT |
| 19:47:53 | $1.40 | 6,000 | $$8K | MIDPOINT |
| 19:47:53 | $1.40 | 1,600 | $$2K | MIDPOINT |
5 dark pool trades shown · $$22K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ADC Therapeutics SA (ADCT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ADCT — frequently asked questions
What is ADCT stock price today?
ADC Therapeutics SA (ADCT) is at $1.41, down 0.35% (-$0.00) at the Nov 13, 2026 close.
Why is ADCT stock moving today?
Latest ADCT news — Nov 9, 2026: ADC Therapeutics SA filed a shelf registration for future offerings (Form S-3) · Nov 10, 2026: ADC Therapeutics Posts Q3 2026 Financials
What is the ADCT price target?
The average analyst price target for ADCT is $5.00, ranging from $2 to $8, based on 3 analysts. Latest: Guggenheim maintains on Aug 17, 2026.
What do analysts rate ADCT?
Analyst ratings for ADCT: 0 Buy, 3 Hold, 3 Sell — consensus Hold.
Did ADCT beat earnings?
ADCT last reported on Aug 13, 2026: EPS -$0.11 vs -$0.22 expected — a beat of 49.1%.
Does ADCT pay a dividend?
ADCT does not currently pay a dividend.
What are ADCT support and resistance levels?
Support: $1.39, $1.06, $0.78. Resistance: $1.70, $3.10, $3.36.
What are insiders doing with ADCT?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on ADCT?
Nov 9, 2026: ADC Therapeutics SA filed a shelf registration for future offerings (Form S-3) · Nov 10, 2026: ADC Therapeutics Posts Q3 2026 Financials · Nov 9, 2026: ADC Therapeutics SA filed a report on a major company event (Form 8-K)